atai Life Sciences Announces Participation in Key Investor Events

Author: Evelyn Baker Updated: 08-28-2025 04:23 PM

atai Life Sciences to Engage with Investors This September

NEW YORK and AMSTERDAM — atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company dedicated to developing groundbreaking treatments for mental health conditions, recently announced its participation in a series of important investor conferences this September. These events present a valuable opportunity for the company to connect with its investors and the broader financial community.

Details of Upcoming Investor Conferences

Here are the specifics regarding atai's participation in several notable events:

Cantor Global Healthcare Conference 2025

Format: Fireside Chat
Date: September 5 at 8:35 a.m. ET
Location: New York

H.C. Wainwright 27th Annual Global Investment Conference

Format: Fireside Chat
Date and Time: September 8 at 11:30 a.m. ET
Location: New York

TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Format: Fireside Chat
Date and Time: September 17 at 10:00 a.m. ET
Location: Virtual

The webcasts of these fireside chats will be accessible through atai’s official website. For those unable to attend the live sessions, recordings will be available afterward, ensuring that all interested stakeholders can catch up on the discussions.

About atai Life Sciences

atai is a dedicated clinical-stage biopharmaceutical firm striving to revolutionize mental health treatment. With a focus on psychedelics-based therapies, the company’s innovative pipeline includes:

BPL-003: Targeting treatment-resistant depression (TRD) with intranasal mebufotenin benzoate, developed in partnership with Beckley Psytech Limited.
VLS-01: A buccal film formulation of DMT, also for TRD.
EMP-01: An oral formulation of R-MDMA, aimed at alleviating social anxiety disorder.

All of these programs are currently in Phase 2 clinical development. In addition to these therapies, atai is spearheading a drug discovery initiative focused on creating novel, non-hallucinogenic 5-HT2AR agonists to provide treatment solutions for TRD.

This forward-thinking approach addresses the intricate challenges surrounding mental health and aims to create scalable solutions that can seamlessly integrate into existing healthcare systems. To stay updated with their initiatives, please visit www.atai.com or connect with the company on LinkedIn.

Contact Information

Investor Contact:
Email: IR@atai.com

Media Contact:
Email: PR@atai.com

Frequently Asked Questions

What is the focus of atai Life Sciences?

atai Life Sciences is focused on developing innovative treatments for mental health disorders, leveraging psychedelic compounds in their therapies.

When are the upcoming investor conference events?

The investor conferences are scheduled for September 5, September 8, and September 17.

How can I access the webcasts of the events?

The webcasts will be available on atai’s website under the Investors section for those who wish to view them live or afterward.

What therapies is atai developing?

atai is currently developing therapies including BPL-003, VLS-01, and EMP-01, which target treatment-resistant depression and social anxiety disorder.

How can I learn more about atai Life Sciences?

You can visit their website at www.atai.com for more information on their therapies, pipeline, and updates.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.